Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer
This study will evaluate the clinical efficacy of combining Gleevec (imatinib mesylate), a PDGFR antagonist, with front-line, single-agent paclitaxel in a cohort of elderly patients with advanced, non-small cell lung cancer.
Non-small Cell Lung Cancer
DRUG: Imatinib mesylate|DRUG: Paclitaxel
Response Rate, Response rates according to RECIST criteria (version 1.0) expressed as percentage of evaluable patients., 6 months
Overall Survival, Overall survival as measured by the Kaplan-Meier method, 12 Months|Progression Free Survival, Number of months post treatment without measurable progression according to RECIST criteria (version 1.0), 12 months|Toxicities, Adverse events of grade 3 or higher, according to CTCAE version 3, 12 months
Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Imatinib 600 mg/day, oral administration in 4-day pulses bracketing each paclitaxel infusion (days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6